深港通（南向）十大活跃成交公司 | 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 阿里巴巴-W(09988) | 35.83 亿元 | -5.15 亿元 | | 小米集团-W(01810) | 23.24 亿元 | +9.72 亿元 | | 腾讯控股(00700) | 19.80 亿元 | -7.96 亿元 | | 中芯国际(00981) | 16.23 亿元 | -1.99 亿元 | | 泡泡玛特(09992) | 12.82 亿元 | +1.30 亿元 | | 信达生物(01801) | 10.95 亿元 | +3619.37 万元 | | 美团-W(03690) | 7.23 亿元 | +1.23 亿元 | | 华虹半导体(01347) | 6.72 亿元 | +1278.26 万元 | | 中国海洋石油(00883) | 6.49 亿元 | +3668.70 万元 | | 长飞光纤光缆(06869) | 5.17 亿元 | -4098.85 万元 | 智通财经APP获悉，2025年12月8日当天，阿里巴巴-W(09988)、中芯国际(00981)、小米集团-W( ...

港股今日承压走低，恒指跌超1%再失守两万六大关。截止收盘，恒生指数跌1.23%或319.72点，报 25965.36点，全日成交额为2062.3亿港元；恒生国企指数跌1.25%，报9083.53点；恒生科技指数平收， 报5662.55点。 中银国际指出，对于近期股市剧烈波动，投资者应保持定力，不易过度担忧，牛市中股市出现调整属于 正常现象，短期震荡不改港股上行趋势。展望2026年，该行相信巩固资本市场回稳向好势头不会改变。 蓝筹股表现 百度集团-SW(09888)领涨蓝筹。截至收盘，涨3.45%，报125.8港元，成交额30.41亿港元，贡献恒指8.38 点。百度集团发布公告，公司注意到，于12月5日有媒体报道公司拟分拆非全资附属公司昆仑芯(北京) 科技有限公司进行独立上市。公司谨此澄清，目前正就拟议分拆及上市进行评估。倘进行拟议分拆及上 市，将须经相关监管审批程序，而公司并不保证拟议分拆及上市将会进行。 其他蓝筹股方面，中芯国际(00981)涨2.94%，报71.8港元，贡献恒指14.49点；中国平安(02318)涨 2.15%，报61.75港元，贡献恒指13.68点；建设银行(00939)跌4.01%，报 ...

其他蓝筹股方面，中芯国际(00981)涨2.94%，报71.8港元，贡献恒指14.49点；中国平安(02318)涨 2.15%，报61.75港元，贡献恒指13.68点；建设银行(00939)跌4.01%，报7.66港元，拖累恒指54.39点；招 商银行(03968)跌3.54%，报51.8港元，拖累恒指11.63点。 热门板块方面 盘面上，大型科技股普遍走低，阿里巴巴跌超1%，腾讯跌0.82%。证监会主席提对优质机构适当"松 绑"，中资券商股逆市上涨；光通信概念股走高，汇聚科技涨超7%；芯片股表现活跃，华虹半导体涨超 4%；锂电股、部分保险股向好。另一边，新版医保药品目录公布，医药股今日高开低走；市场静待本 周美联储议息会议，黄金股集体下跌；煤炭、内银股、新消费股等下挫。 1. 中资券商股逆市上涨。截至收盘，华泰证券(06886)涨5.17%，报19.33港元；广发证券(01776)涨 3.1%，报17.94港元；中信建投证券(06066)涨2.99%，报12.76港元；招商证券(06099)涨2.82%，报15.29 港元。 智通财经APP获悉，港股今日承压走低，恒指跌超1%再失守两万六大关。截止收盘，恒生 ...

Core Insights - The global biopharmaceutical innovation landscape, traditionally dominated by multinational corporations, is undergoing significant structural changes, with China's innovative drug industry emerging as a key player on the global stage [1] - China's transition from a "fast follower" to an "originator" in innovative drugs is becoming an irreversible trend, as highlighted by international media [1] - Data shows a notable increase in China's share of global clinical trials and licensing transactions, with Chinese biotech companies outperforming their U.S. counterparts in stock price growth over the past year [1][3] Group 1: Market Dynamics - Multinational corporations are increasingly inclined to source early-stage innovative pipelines from China due to cost-effectiveness, with costs in China being 30%-40% lower than in the U.S. [2] - The collaboration between domestic companies and multinationals is exemplified by the $12.5 billion upfront payment from Pfizer to 3SBio for overseas rights to a bispecific antibody, marking a record for domestic innovative drugs [2][3] - The Chinese innovative drug sector is expected to see a surge in licensing transactions, with projections indicating that total licensing amounts could exceed $100 billion in the first three quarters of 2025 [3] Group 2: Investment Trends - The biopharmaceutical sector is experiencing a business development (BD) boom, with significant transactions such as the $12 billion collaboration between Hengrui Medicine and GSK, indicating strong interest from multinational companies [3][4] - Investment institutions are focusing on the biopharmaceutical sector, with approximately 80% of the market value concentrated in biotechnology and pharmaceuticals, driving capital flow into these areas [5] - The market is witnessing a shift from "story-driven" investment decisions to a focus on the hard capabilities of companies, emphasizing the importance of clinical data and product quality [9][10] Group 3: Future Outlook - The innovative drug market is expected to thrive, with projections indicating that the Hang Seng Index could double by 2025, driven by favorable policies and a rebound in industry valuations [7] - The Chinese innovative drug sector is anticipated to recover strongly in 2025, with the overall revenue of listed companies in this sector reaching 48.83 billion yuan, a 22% year-on-year increase [7] - The market is seeing a resurgence in IPO activity, with over 20 companies currently queued for listing in Hong Kong, reflecting renewed investor interest in the biopharmaceutical sector [12][13]

"当然好消息是现在有药品了如果你有强大的意志力，通过运动饮食管好体重是最好的。如果你做不 到，有三种药可以用了，首先是司美格鲁肽，后来是礼来的替尔泊肽，最新的信达的玛仕度肽，只要是 24以上的BMI超重了，要加上一种相关的这些综合症，有比如血脂、血压不正常就能服用这个药，效果 也很好。"他说。 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 责任编辑：李思阳 专题：2025《中国企业家》影响力企业家年会 爱康集团创始人、董事长兼CEO张黎刚在2025（第二十三届）影响力企业家年会表示，企业家要年轻， 第一大因素把体重管好了。如果你体重没有管好，怎么都不可能看上去年轻，所以体重是第一重要的， 我们看一下企业家当中一半以上都是超重的。 专题：2025《中国企业家》影响力企业家年会 爱康集团创始人、董事长兼CEO张黎刚在2025（第二十三届）影响力企业家年会表示，企业家要年轻， 第一大因素把体重管好了。如果你体重没有管好，怎么都不可能看上去年轻，所以体重是第一重要的， 我们看一下企业家当中一半以上都是超重的。 "当然好消息是现在有药 ...

每经AI快讯，信达生物(01801.HK)跌逾5%，截至发稿跌5.43%，报87港元，成交额18.6亿港元。 ...

Core Viewpoint - The stock of Innovent Biologics (01801) has experienced a significant decline of over 6%, currently trading at 87 HKD with a transaction volume of 1.86 billion HKD, despite the inclusion of seven innovative products in the new medical insurance directory [1] Group 1: Product Developments - Innovent Biologics has successfully included seven innovative products, including the PD-1 inhibitor Tyvyt (sintilimab injection), in the new medical insurance directory, expanding the indications for mature products [1] - With the recent addition of indications, Tyvyt now has all eight approved indications covered by medical insurance [1] - The new drugs included in the directory target areas such as oncology and chronic diseases [1] Group 2: Financial Transactions - Innovent Biologics has completed a share issuance to Takeda Pharmaceutical, issuing 6.9138 million shares, which accounts for approximately 0.4% of the total issued share capital, raising nearly 780 million HKD in net proceeds [1] - There have been significant large transactions in the market, involving approximately 13.0734 million shares at an average price of 92 HKD per share, totaling over 1.2 billion HKD [1]

Core Viewpoint - The stock of Innovent Biologics (01801) has experienced a significant decline of over 6%, currently trading at 87 HKD with a transaction volume of 1.86 billion HKD, despite the inclusion of seven innovative products in the new medical insurance directory [1] Group 1: Product Developments - Innovent Biologics has successfully included seven innovative products, including the PD-1 inhibitor Tyvyt (sintilimab injection), in the new medical insurance directory, expanding the indications for mature products [1] - With the recent additions, all eight approved indications for Tyvyt are now covered by medical insurance, which may enhance market access and patient affordability [1] Group 2: Financial Transactions - The company has completed a share issuance to Takeda Pharmaceutical, issuing 6.9138 million shares, which represents approximately 0.4% of the total issued share capital, raising nearly 780 million HKD in net proceeds [1] - There have been significant large transactions in the market, involving approximately 13.0734 million shares at an average price of 92 HKD per share, totaling over 1.2 billion HKD [1]

SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced the initial data of the first-in-human trial of IBI3003, a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation ant ...

Group 1 - The top three stocks with the highest short-selling ratios are New World Development Co. Ltd. (100.00%), China Resources Beer (100.00%), and AIA Group Ltd. (100.00%) [1][2] - The stocks with the highest short-selling amounts are Xiaomi Corporation (2.196 billion), Ping An Insurance (1.956 billion), and Alibaba Group (1.160 billion) [1][3] - The stocks with the highest deviation values are Bank of China (52.21%), China Mobile (41.86%), and Café de Coral Holdings (40.03%) [1][2] Group 2 - The top ten short-selling ratio rankings include New World Development Co. Ltd. (100.00%), China Resources Beer (100.00%), and AIA Group Ltd. (100.00%) [2] - The top ten short-selling amounts include Xiaomi Corporation (2.196 billion), Ping An Insurance (1.956 billion), and Alibaba Group (1.160 billion) [3] - The top ten deviation values include Bank of China (52.21%), China Mobile (41.86%), and Café de Coral Holdings (40.03%) [3]